Swiss chemical company Lonza is expanding its automated robotic solution for endotoxing testing in the pharmaceutical and biomedical industries.
The biotech firm’s PyroTec Pro system has been designed to ensure the safety of pharmaceuticals, including parenteral medicines and injectable devices.
A new PyroWave reader add-on has been designed specifically for use with the sustainable PyroGene recombinant factor C (rFC) assay.
It is built upon the original release of Lonza’s PyroTec Pro automated system, which includes two absorbance readers for conventional LAL-based assays.
Lonza said the solution has been designed to easily accommodate different assay types in the same run and comes powered by WinKQCL endotoxin analysis software.
According to the company, this complete system further increases the efficiencies and data integrity gained from automated endotoxin testing.
The PyroGene rFC assay is an animal-free method for endotoxin detection that works through a single enzymatic step.
It has reportedly been shown to be equivalent to other photometric endotoxin methods that use LAL to detect endotoxins.
These parameters include linearity, specificity, precision, accuracy, and limit of detection.
The expansion also brings a third test type option to the platform, allowing QC microbiologists to choose the endotoxin test method best suited for their testing needs.
It also expands the options available for streamlined, automated endotoxin testing.
Orla Cloak, director of testing and informatics solutions, Lonza BioScience, said: “This new addition to our established PyroTec PRO solution provides laboratories with greater ability to reduce errors and increase throughput while retaining their trusted endotoxin method.
“Customers can utilise the best method for their specific sample requirements while also furthering their efforts to more fully automate the QC lab and increase utilisation of sustainable solutions.”
